Natalizumab (Tysabri) prior authorization at Blue Cross Blue Shield of Massachusetts
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Blue Cross Blue Shield of Massachusetts requires prior-authorization documentation for Natalizumab (Tysabri): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Blue Cross Blue Shield of Massachusetts reviews Natalizumab (Tysabri) prior authorizations against its medical policy . Blue Cross Blue Shield of Massachusetts-specific context: Non-profit; ~3M members. MA has the most expansive state mandated benefits in the US and strong supplemental parity rules. MA OPP (Office of Patient Protection) provides external review separately from carriers — distinct from federal IRO process for fully-insured plans.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Blue Cross Blue Shield of Massachusetts's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- MA-specific mandated benefit disputes (most generous in US)
- Behavioral health parity (MA has tighter parity rules than federal MHPAEA)
- Tiered-network provider disputes
- Specialty drug PA
Natalizumab (Tysabri)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- JC virus antibody index threshold restrictions
- Step therapy requiring oral DMT first
- Plan-mandated biosimilar switch (Tyruko approved 2023)
- Site-of-care reduction
Brand: Tysabri. α4-integrin antagonist for relapsing MS. REMS-restricted (TOUCH program) due to PML risk. Biosimilar Tyruko (natalizumab-sztn) FDA-approved August 2023 — plans now mandating switch.
Manufacturer patient-assistance program: Biogen Support Services — relevant when a Blue Cross Blue Shield of Massachusetts denial sticks and the patient needs bridge access while appealing.
How Blue Cross Blue Shield of Massachusetts approaches Biologic drugs (mAbs and biosimilars) PAs
For Natalizumab, check whether the current Blue Cross Blue Shield of Massachusetts Biologic drugs (mAbs and biosimilars) policy cites specialty drug pa. Pharmacy-benefit review for Natalizumab at Blue Cross Blue Shield of Massachusetts is routed through Express Scripts. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Blue Cross Blue Shield of Massachusetts; if denied, use the filing date and route printed on that denial notice. Blue Cross Blue Shield of Massachusetts's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Blue Cross Blue Shield of Massachusetts is domiciled in MA, so unresolved appeals escalate to the MA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://provider.bluecrossma.com) with the same packet plus an applicable, current clinical source supporting Natalizumab (Tysabri)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Blue Cross Blue Shield of Massachusetts denial on DenialHelp.
Contact Blue Cross Blue Shield of Massachusetts
- Provider portal: https://provider.bluecrossma.com
Frequently asked questions
What documentation does Blue Cross Blue Shield of Massachusetts need for Natalizumab (Tysabri) prior auth?
Blue Cross Blue Shield of Massachusetts's typical PA packet for Natalizumab (Tysabri): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Blue Cross Blue Shield of Massachusetts?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for Natalizumab (Tysabri) at Blue Cross Blue Shield of Massachusetts?
Preparation scenarios to check against the current notice and policy include: MA-specific mandated benefit disputes (most generous in US); Behavioral health parity (MA has tighter parity rules than federal MHPAEA); Tiered-network provider disputes. These are not measured frequency claims. For Natalizumab (Tysabri), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
What prior failures does Blue Cross Blue Shield of Massachusetts typically require before approving Natalizumab?
Blue Cross Blue Shield of Massachusetts's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For Natalizumab, attach the specific disease-activity instrument Blue Cross Blue Shield of Massachusetts accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Express Scripts. External-review escalation for Blue Cross Blue Shield of Massachusetts fully-insured policies sits with the MA insurance department.
How do I prep for a peer-to-peer with Blue Cross Blue Shield of Massachusetts on Natalizumab (Tysabri)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
- Adalimumab at Blue Cross Blue Shield of Massachusetts
- Aflibercept at Blue Cross Blue Shield of Massachusetts
- Apixaban at Blue Cross Blue Shield of Massachusetts
- Atezolizumab at Blue Cross Blue Shield of Massachusetts
- Natalizumab (Tysabri) at UnitedHealthcare
- Natalizumab (Tysabri) at Elevance Health
- Natalizumab (Tysabri) at Aetna
Generate the Natalizumab (Tysabri) PA packet
Open ApprovalHelp — generate a Natalizumab (Tysabri) prior-auth packet tailored to Blue Cross Blue Shield of Massachusetts's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com